Grifols has a total of 3834 patents globally, out of which 2039 have been granted. Of these 3834 patents, more than 65% patents are active. United States of America is where Grifols has filed the maximum number of patents, followed by Europe and Spain. Parallelly, United States of America seems to be the main focused R&D centre and Spain is the origin country of Grifols.
Grifols was founded in the year 1940. The Company develops, manufactures and markets plasma derivatives, IV Therapy, enteral nutrition, diagnostic systems and medical materials. As of April 2023, the market cap of Grifols is $6.02 Billion.
Do read about some of the most popular patents of Grifols which have been covered by us in this article and also you can find Grifols patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Grifols patent portfolio.
How many patents does the founder and the CEO of Grifols have?
The founder Josep Antoni Grífols has 0 patent and CEO Grífols Roura has 0 patent.
How many patents does Grifols have?
Grifols has a total of 3834 patents globally. These patents belong to 640 unique patent families. Out of 3834 patents, 2507 patents are active.
How Many Patents did Grifols File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Grifols Applications Filed | Grifols Patents Granted |
| 2023 | 5 | 18 |
| 2022 | 61 | 110 |
| 2021 | 192 | 139 |
| 2020 | 228 | 126 |
| 2019 | 240 | 155 |
| 2018 | 237 | 154 |
| 2017 | 229 | 175 |
| 2016 | 210 | 211 |
| 2015 | 189 | 187 |
| 2014 | 83 | 121 |
| 2013 | 311 | 96 |
| 2012 | 260 | 93 |
Explore the top-performing drugs that dominate the Pharmaceutical Industry
| Patent Number | Company | Product | Brand | Revenue | Patent Expiry Date |
| US9174975 | Sumitomo Pharma | Lurasidone Hydrochloride | Latuda | $1.75B | Jun-26 |
| US7612199 | Alfasigma | Rifaximin | Xifaxan | $1.64B | Nov-24 |
| US7902206 | Alfasigma | Rifaximin | Xifaxan | $1.64B | Nov-24 |
| US8158644 | Alfasigma | Rifaximin | Xifaxan | $1.64B | Nov-24 |
| US7371727 | Ironwood Pharma | Linaclotide | Linzess | $1.00B | Mar-25 |
Want to know which drugs are making over $1 Billion annually?
How many Grifols patents are Alive/Dead?
How Many Patents did Grifols File in Different Countries?
Countries in which Grifols Filed Patents
| Country | Patents |
| United States Of America | 422 |
| Europe | 312 |
| Spain | 224 |
| Germany | 190 |
| Canada | 186 |
| Australia | 179 |
| Japan | 164 |
| Hong Kong (S.A.R.) | 136 |
| China | 130 |
| Brazil | 129 |
| Korea (South) | 118 |
| Mexico | 115 |
| Israel | 101 |
| Singapore | 91 |
| Poland | 89 |
| New Zealand | 88 |
| Portugal | 83 |
| Argentina | 81 |
| South Africa | 81 |
| India | 80 |
| Russia | 73 |
| Chile | 71 |
| Taiwan | 60 |
| Indonesia | 52 |
| Uruguay | 52 |
| Hungary | 46 |
| Denmark | 45 |
| Malaysia | 41 |
| Austria | 36 |
| United Kingdom | 27 |
| Norway | 22 |
| Slovenia | 17 |
| Italy | 17 |
| Turkey | 16 |
| Colombia | 16 |
| Croatia | 9 |
| Viet Nam | 7 |
| Costa Rica | 7 |
| Slovakia | 6 |
| Philippines | 6 |
| Cyprus | 5 |
| Malta | 5 |
| Serbia | 4 |
| Albania | 3 |
| Ukraine | 3 |
| Lithuania | 3 |
| Gulf Cooperation Council | 2 |
| United Arab Emirates | 2 |
| Czech Republic | 2 |
| Montenegro | 1 |
| Republic of Moldova | 1 |
| Tunisia | 1 |
| Former Yugoslav Republic of Macedonia | 1 |
| Belgium | 1 |
| Eurasia | 1 |
| Luxembourg | 1 |
| Morocco | 1 |
Where are Research Centres of Grifols Patents Located?
10 Best Grifols Patents
US6676664B1 is the most popular patent in the Grifols portfolio. It has received 268 citations so far from companies like Celonova Biosciences, Aoi Medical and Lanx.
Below is the list of 10 most cited patents of Grifols:
| Publication Number | Citation Count |
| US6676664B1 | 268 |
| US20140057799A1 | 255 |
| US7198923B1 | 185 |
| WO2009080829A1 | 115 |
| WO2013096643A1 | 102 |
| US20020045854A1 | 96 |
| US6514731B1 | 70 |
| US6355243B1 | 62 |
| US20150031555A1 | 57 |
| WO2010128087A2 | 56 |
How many inventions of other companies were rejected due to Grifols patents?
The statistics below share strategic R&D insights. It tells the companies that were trying to protect inventions similar to Grifols invention. They couldn’t because Grifols had protected those before them.
Examiners at the USPTO referred 94 Grifols patents in 441 rejections (35 USC § 102 or 35 USC § 103 types).
The top citing companies in the Grifols patent portfolio are 10X Genomics, Alkahest and Biotest.
List of the Companies whose Patents were rejected citing Grifols –
| Company | Number of Patent Applications that faced Rejection Citing Grifols Patents | Number of Rejections (102 & 103) |
| 10X Genomics | 10 | 24 |
| Alkahest | 9 | 29 |
| Biotest | 7 | 27 |
| Pacira Pharmaceuticals | 6 | 17 |
| Biomat | 4 | 30 |
| Araclon Biotech | 4 | 21 |
| Csl Limited | 4 | 9 |
| Roche Holding | 3 | 8 |
| Bank Of America | 3 | 4 |
| President And Fellows Of Harvard College | 2 | 3 |
Count of 102 and 103 Type Rejections based on Grifols Patents
Top Grifols Patents used in Rejecting Most Patent Applications
| Patent Number | Count of Rejected Applications |
| US20140057799A1 | 15 |
| US8071127B2 | 7 |
| US20060045877A1 | 6 |
| US20120244206A1 | 6 |
| US20020045854A1 | 5 |
| US6676664B1 | 5 |
| US6537745B2 | 5 |
| US7544500B2 | 5 |
| US8278302B2 | 4 |
| US20090162362A1 | 4 |
| US6462180B1 | 4 |
| US6936442B2 | 4 |
| US6875848B2 | 3 |
| US8234207B2 | 3 |
| US8119156B2 | 3 |
What Percentage of Grifols US Patent Applications were Granted?
Grifols (Excluding its subsidiaries) has filed 209 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 178 have been granted leading to a grant rate of 86.41%.
Below are the key stats of Grifols patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Grifols?
| Law Firm | Total Applications | Success Rate |
| Womble Bond Dickinson | 39 | 74.36% |
| Dinsmore & Shohl | 28 | 96.15% |
| Novartis Vaccines | 23 | 95.65% |
| Leason Ellis | 19 | 89.47% |
| Polsinelli | 15 | 100.00% |
| Knobbe Martens Olson & Bear | 13 | 92.31% |
| Reed Smith | 12 | 75.00% |
| Chiron Corporation | 8 | 100.00% |
| Barnes & Thornburg | 6 | 83.33% |
| Christie Parker & Hale | 6 | 100.00% |